Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia

Drugs under Experimental and Clinical Research

Volumn 25, Issue 6, 1999, Pages 243-252

  Bartoloni, A ^a   Strohmeyer, M ^a   Corti, G ^a   Buonomini, M I ^b   Franchino, L ^c   Romanelli, G ^d   Moretti, A M ^e   De Vizzi, G B ^f   Petraglia, A ^g   Mancini, P ^h   Atzeni, R ⁱ   Fogliani, V ^j   Glura, R ^k   Paradisi, F ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b Microbiology   (Italy)

^c Medical Department   (Italy)

^d UNIVERSITY OF BRESCIA   (Italy)

^e Department of Pneumology   (Italy)

^f C Cantù Hospital   (Italy)

^g G Da Procida Hospital   (Italy)

^h SAN CAMILLO FORLANINI HOSPITAL   (Italy)

ⁱ C Zonchello Hospital   (Italy)

^j Ospedale di Milazzo   (Italy)

^k SANT ANNA HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CILASTATIN PLUS IMIPENEM; MEROPENEM;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RASH; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CILASTATIN; COMMUNITY-ACQUIRED INFECTIONS; DRUG THERAPY, COMBINATION; DRUG TOLERANCE; FEMALE; HUMANS; IMIPENEM; MALE; MIDDLE AGED; PNEUMONIA, BACTERIAL; SAFETY; THIENAMYCINS;

EID: 0033382529     PISSN: 03786501     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Kahan F.M., Kropp H., Sundelof J.G., et al. Thienamycin: Development of imipenem-cilastatin. J. Antimicrob. Chemother., 12 (Suppl. D), 1, 1983.
2. Jones R.N., Barry A.L., Thornsberry C. In-vitro studies of meropenem. J. Antimicrob. Chemother., 24 (Suppl. A), 9, 1989.
3. Bartoloni A., Colao M.G., Orsi A., Nicoletti P., Corti G., Paradisi F. Comparative in vitro activity of meropenem against Italian clinical Isolates of Gram-negative and Gram-positive aerobic and Gram-negative anaerobic bacteria. Rev. Esp. Quimioter., 5 (Suppl. 4), 49, 1992.
4. Norrby S.R., Faulkner K.L., Newall P.A. Differentiating meropenem and imipenem/cilastatin. Infect. Dis. Clin. Pract., 6, 291, 1997.
5. Birnbaum J., Kahan F.M., Kropp H., MacDonald S. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am. J. Med., 78 (Suppl. A), 3, 1985.
6. Norwegian Study Group. Imipenem/cilastatin as monotherapy in severe infections: Comparison with cefotaxime in combination with metronidazole and cloxacillin. Scand. J. Infect. Dis., 19, 667, 1987.
7. Colardyn F., Faulkner K.L. on behalf of the Meropenem Serious Infection Study Group. Intravenous meropenem vs. imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. J. Antimicrob. Chemother., 38, 523, 1996.
8. Mouton Y.J., Beuscart C., the Meropenem Study Group. Empiric monotherapy with meropenem in serious bacterial infections. J. Antimicrob. Chemother., 36 (Suppl. A), 145, 1995.
9. Mouton Y., Debosker Y., Bazin C., et al. Prospective, randomised controlled trial of imipenem/cilastatin vs. cefotaxime-amikacin in the treatment of lower respiratory tract infections and septicemia in intensive care units. Presse Med., 19, 607, 1990.
10. Bauer A.W., Kirby W.M.M., Sherris J.C., Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am. J. Clin. Pathol., 45, 493, 1966.